References
- AbdelsalamADel PrioreLZarbinMA1999Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regressionSurv Ophthalmol4412910466585
- AugustinAJD’AmicoDJMielerWF2005Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degenerationGraefes Arch Clin Exp Ophthalmol24391215290154
- AugustinAJSchmidt-ErfurthU2006Verteporfin therapy combined with intravitreal triamcinolone in al types of choroidal neovascularization due to age related macular degenerationOphthalmology11142216360209
- BenEzraDGriffinBWMaftzirG1997Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularizationInvest Ophthalmol Vis Sci581954629331259
- BleiFWilsonELMignattiP1993Mechanism of action of angiostatic steroids: Suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesisJ Cell Physiol155568787684043
- ChristenWGGlynnRJMansonJE1996A prospective study of cigarette smoking and age-related macular degeneration in menJAMA2761147518827967
- ClarkAFPennJS2003eLetter to the Editor: PAI-1 and ocular angiogenesis [online] Accessed on 12 August 2005. URL: http://www.iovs.org/cgi/eletters/44/6/2791
- ClarkAFYorioT2003Ophthalmic drug discoveryNat Rev Drug Discov24485912776220
- ClarkAFBingamanDPKapinMA2000Ocular angiostatic agentsExp Opin Ther Patents10427448
- ClarkAFMellonJLiXY1999Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetateInvest Ophthalmol Vis Sci4021586210440274
- ClarkAF1997AL-3789: A novel ophthalmic angiostatic steroidExp Opin Invest Drugs6186777
- CrumRSzaboSFolkmanJ1985A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragmentScience230137582416056
- D’AmicoDJGoldbergMFHudsonH2003Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD); Interim (month 6) analysis of clinical safety and efficacyRetina23142312652226
- DeFallerJMClarkAF2000A new pharmacological treatment for angiogenesisTaylorHRPterygiumThe Hague, NetherlandsKugler Pub15981
- GragoudasESAdamisAPCunninghamETJrVEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group2004Pegaptanib for neovascular age-related macular degenerationN Engl J Med35128051615625332
- HammWTJrMuellerHASlineyDH1976Retinal sensitivity to damage from short wavelength lightNature260153815821
- KijlstraALa HeijEHendrikseF2005Immunological factors in the pathogenesis and treatment of age-related macular degenerationOcul Immunol Inflamm1331115804763
- KleinRKleinBELintonKL1992Prevalence of age-related maculopathy: The Beaver Dam Eye StudyOphthalmology99933431630784
- LiuCGuXWangW-H2005Local delivery of anecortave acetate inhibits the expression of retinal IGF-1/IGF-1 receptor in the rat OIR model [abstract]Invest Ophthalmol Vis SciARVO 4135
- McNattLGWeimerLYanniJ1999Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularizationJ Ocul Pharmacol Ther154132310530702
- NewsomeDASwartzMLeoneNC1998Oral zinc in macular degenerationArch Ophthalmol61928
- PennJSRajaratnamVCollierRJ2001The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurityInvest Ophthalmol Vis Sci422839011133880
- RegilloCDD’AmicoDMielerW2005Safety outcomes of clinical studies for anecortave acetate in patients with exudative age-related macular degeneration [abstract]Invest Ophthalmol Vis SciARVO 1373
- SeddonJMAjaniUASperdutoRD1994Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study GroupJAMA2721413207933422
- SeddonJMRosnerBSperdutoRD2001Dietary fat and risk for advanced age-related macular degenerationArch Ophthalmol1191191911483088
- SeddonJMWillettWCSpeizerFE1996A prospective study of cigarette smoking and age-related macular degeneration in womenJAMA276114168827966
- SlakterJSBochowTD′AmicoDJ2006Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degenerationOphthalmology11331316368146
- SlakterJSJerdanJKaneFE2005Baseline characteristics of a Phase 3 clinical study of anecortave acetate 15 mg in patients with exudative age-related macular degeneration (AMD) [abstract]Invest Ophthalmol Vis SciARVO 1374
- SwannPGLovie-KitchinJE1990Age-related maculopathy; I. A review of its morphology and effects on visual functionOphthalmic Physiol Opt10149582196510
- TaylorHRMunozBWestS1990Visible light and risk of age-related macular degenerationTrans Am Ophthalmol Soc8817380
- VingerlingJRHofmanAGrobbeeDE1996Age-related macular degeneration and smoking. The Rotterdam StudyArch Ophthalmol114119368859077
- VingerlingJRKlaverCCHofmanA1995Epidemiology of age-related maculopathyEpidemiol Rev17347608654516
- YangRMcCollumGWBingamanDP2005The effect of anecortave acetate on VEGF message and protein levels in hypoxic Müller cells and in rat OIR [abstract]Invest Ophthalmol Vis SciARVO 4177